[email protected]   +1 (304) 306-0723

Gamma Delta T cell Therapy-Pipeline Analytics 2021

$2,500.00$7,500.00

Gamma Delta T cell Therapy report covers the Gamma Delta T cell Therapy market opportunity providing Key Competitive Analysis, 30+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, company and phases, therapy area and indications by phases. Gamma Delta T cell Therapy reports adds a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in understanding the developmental pipeline with respect to different types of molecules, line of therapy and route of administration (RoA).

Clear
SKU: MM202039 Category:

Description

A new wave of therapies based on a unique type of immune cells, called Gamma Delta T cell Therapy, has the potential to treat cancer with stronger responses and fewer side effects. Immunotherapies based on gamma delta T cells are becoming a huge trend in the treatment of cancer and play a role in the innate immune response, which constitutes the first, faster line of defense of the immune system. As gamma delta T cells are part of the innate immune system, they are already pre-programmed to locate and destroy cells that are ‘stressed’ by cancer-associated transformation.

In this report, Mellalta Meets provides an in-depth analyzes γδ T cells profiles covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy area, investments, and acquisition trends. The report also adds value in terms of providing the current market opportunity, drivers, and challenges.

As per analysis, the development pipeline is full of directly allogeneic and autologous γδ T cells therapies. The major key players operating in the market are Acopedia, Takeda Pharma, TC Biopharma and Adapate Therapeutics which have robust clinical pipeline of gamma delta T cells candidates.

Key Highlights of Gamma Delta T cell Therapy Report

  • There are ~24 products in the Preclinical stage of development, representing 73% of the total share of the developing gamma delta T cells landscape.
  • The pipeline of γδ T cells therapy is dominated by biotech companies headquartered in the United States with the American companies holding the top ten positions. They represent ~50% of all the pipeline γδ T cells therapy in clinical stages.

Gamma Delta T cell Therapy Pipeline Landscape

  • Oncology represents ~ 91% of the total γδT therapies while the therapy areas namely Autoimmune Diseases and Respiratory Diseases occupy the remaining 9% of the γδ T Trials.
  • The pipeline of γδT therapies is dominated by Solid Tumors and Haematological Malignancies with the Preclinical (6) assets and Phase I (1) assets.
  • Allogeneic gamma delta T Cell products represents ~ 52% of the total γδT therapies while the other molecule types mainly include Allogeneic gamma delta T Cell therapy and Monoclonal Antibody, which occupy the 21% and 27% of the γδ T products.
  • To be continued…

 

Report Coverage:

  • Indication Prioritisation: Gamma Delta T cell Therapy market potential based on Indications
  • Business Transactions & Strategies: Key collaborations and deal values
  • Gamma Delta T cell Therapy Pipeline Development: Product Profiles, Clinical Trials & Results
  • Gamma Delta T cell Therapy Acquisition Targets
  • Gamma Delta T cell Therapy Competitive Intelligence
  • Recent & Upcoming events

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • OVERVIEW
  • The Gamma Delta (γδ)T cell Therapy Target BACKGROUND
    • Emerging Role of T Cell Based Immunotherapies
    • Gamma Delta T cell Therapy- Overview
    • Gamma Delta T cell -Mechanisms
    • Gamma Delta T (γδ T) cells – Characteristics
    • Gamma Delta T Cell Therapy Vs. Other Therapies (CAR T Cell Therapy/ Tumor Infiltrating Lymphocyte Therapy/ Immune Checkpoint Inhibitors
    • Unique Features of Gamma Delta T (γδ T) cells over αβ T cells in Cancer
    • Strategies to target Gamma Delta T (γδ T) cells in Cancer
    • Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients
  • Gamma Delta (γδ)T cell therapy PIPELINE ANALYSIS by Phases
    • Overview
    • Assets by Indication/Phase
    • Pipeline Products by Stage of Development
    • Gamma Delta (γδ) T cell Competitive Landscape by Phases
    • Pipeline Products by Company and Phases
    • Pipeline Products by Therapy Area
    • Pipeline Products by Indication and Phases
    • Gamma Delta (γδ) T cells therapy Pipeline analysis by Molecule Type
  • Gamma Delta (γδ) T cells therapy Licensing and Collaboration deals
    • Gamma Delta (γδ) T cells therapy Licensing by Transaction type and total amount size by Phases
    • Gamma Delta (γδ) T cells therapy Licensing, Acquisition and Deal values
  • Gamma Delta (γδ) T cells therapy Pipeline Landscape
    • Profile at Glance
    • Gamma Delta (γδ) T cells therapy Pipeline Drug Profiles
      • Phase I/II
        • Lava Therapeutics N.V.: LAVA -051
          • Product Profile & Description
          • Collaborations
          • Other Developments 
          • Clinical Trials
        • Phase I
          • TC BioPharm:OmnImmune
            • Product Profile & Description
            • Collaborations
            • Other Developments 
            • Clinical Trials 
          • IN8bio: INB-200
            • Product Profile & Description
            • Collaborations
            • Other Developments 
            • Clinical Trials
          • IN8bio: INB-100
            • Product Profile & Description
            • Collaborations
            • Other Developments 
            • Clinical Trials
          • Gadeta: TEG-001
            • Product Profile & Description
            • Collaborations
            • Other Developments 
            • Clinical Trials 
          • Gadeta: GDT-002
            • Product Profile & Description
            • Collaborations
            • Other Developments 
            • Clinical Trials 
          • Adicet Bio: ADI-001
            • Product Profile & Description
            • Collaborations
            • Other Developments 
            • Clinical Trials
          • Cytomed Therapeutics:CTM-N2D
            • Product Profile & Description
            • Collaborations
            • Other Developments 
            • Clinical Trials
          • ImCheck Therapeutics: ICT-01
            • Product Profile & Description
            • Collaborations
            • Other Developments 
            • Clinical Trials
          • Preclinical
            • TC BioPharm: TCB-007
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • IN8bio: INB-400
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • IN8bio: INB-300
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • Gadeta:TEG-201
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • Adicet Bio:ADI-002
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • Hebei Senlang Biotechnology:Senl_GDUCARxxx
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • GammaDelta Therapeutics Ltd/Takeda:GDX-012
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • Acepodia: ACE-1813
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • Acepodia:  ACE-1708
          • Product Profile & Description
          • Collaborations
          • Other Developments 
            • Acepodia:ACE-1975
          • Product Profile & Description
          • Collaborations
          • Other Developments 
            • Acepodia: ACE-2023
          • Product Profile & Description
          • Collaborations
          • Other Developments 
            • Kiromic Biopharma:KB-PD1
          • Product Profile & Description
          • Collaborations
          • Other Developments 
            • Kiromic Biopharma:  KB-ISM
          • Product Profile & Description
          • Collaborations
          • Other Developments 
            • AdaptateBiotherapeutics: ADT-010
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • Immatics :IMA-301
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • ImCheck Therapeutics: ICT-04
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • ImCheck Therapeutics:ICT-05
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • ImCheck Therapeutics: ICT-06
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • ImCheckTherapeutics: ICT-07
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • ImCheck Therapeutics:ICT-08
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • ImCheck Therapeutics : ICT-21
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • ImCheck Therapeutics :ICT-23
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • PureTech Health plc :  LYT-210
              • Product Profile & Description
              • Collaborations
              • Other Developments 
            • Gamma Delta T Cell Therapy Market Overview
              • Current Market Scenario
              • Market Potential of Gamma Delta T Cell Therapy-Market Drivers & Barriers
            • Gamma Delta T Cell Therapy Future Prospects
            • SWOT Analysis
            • Appendix

Companies Coverage

  • Acepodia
  • Adaptate Biotherapeutics
  • Adicet Bio
  • Cytomed Therapeutics
  • Gadeta
  • GammaDelta Therapeutics Ltd/Takeda
  • Hebei Senlang Biotechnology
  • ImCheck Therapeutics
  • Immatics
  • IN8bio
  • Kiromic Biopharma
  • Lava Therapeutics N.V.
  • PureTech Health plc
  • TC BioPharma
  • Others
Name
Email
Phone
Enquiry

Get In Touch

Let's keep the conversation going